Applied Clinical Trials-08-01-2020

Recent case study highlights the importance of applying statistical rigor throughout the development and validation processes of biomarkers.

Distinguishing CAR-T and CPI approaches and the clinical trial challenges and complexities associated with each.

While clinical trials are starting to make a return from COVID-19-related interruptions, cracks in their traditional operation are being exposed.

An amendment to Pediatric Research Equity Act, as part of the 2017 FDA Reauthorization Act, goes into effect soon aiming to change the landscape and promote pediatric cancer drug development.

A look at one company’s platform approach in enabling the engineering of T-cells to identify and destroy cancer.

Click here for a link to open the Applied Clinical Trials August 2020 issue in an interactive PDF format.

Exploring the benefits of capturing and integrating molecular biomarker data within clinical trials to build foundations for data assets.

Amid the COVID-19 pandemic, the EU is allowing trials to start before the requirements of directives dating back as far as 2001 have been met.

Firma Clinical Research CEO Michael Woods shares why COVID-19 may force greater efficiency for trial designs and greater access for trial participants.

A compilation of recent notable news developments that pertain to the clinical trials industry.

Perspectives and insights regarding regulatory considerations when planning and conducting immunotherapy studies.

The increasing need for treatments to slow the global spread of COVID-19 has prompted greater cooperation between drug regulatory authorities around the world.

If you are an organization content with patient-centric approaches, you are behind. Today it is about patient-driven drug development.